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Chlamydia trachomatis is the leading cause of bacterial 
sexually transmitted infection (STI) in humans.[1] The 
prevalence of C. trachomatis infection has been rising 
progressively in many countries, with >100 million new cases 
estimated annually around the globe (WHO).[2] An estimated 
3–4 million new cases occur every year in the US, 5 million in 
Western Europe and 16 million in Sub-Saharan Africa.[3] The 
largest burden of C. trachomatis infection occurs in women, 
where complications can include pelvic inflammatory disease. 
However, because patients with C. trachomatis urogenital 
infections often do not exhibit any symptoms (75%–90% 
of patients), they remain undiagnosed and untreated. This 
can lead to tubal factor infertility, miscarriage or ectopic 
pregnancy.[4-6] Genital Chlamydia infections also increase 
the susceptibility to other sexually transmitted agents, such 
as HIV.[7]
Repeated chlamydial genital infections are common and 
account for a substantial proportion of incident infections.[8] 
Although C. trachomatis infections can be treated effectively 
with antibiotics such as azithromycin, or doxycycline, almost 
one-fourth of individuals are re-infected with C. trachomatis.[9] 
Repeated infections result from failure of antibiotic therapy or 
from reinfection due to continued unprotected sexual contact 
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with either an untreated existing partner or a new infected 
partner.[8] Chlamydia reinfection incidence and treatment 
failure is rising with high repeat C. trachomatis infection rates 
observed in community cohorts of women in the UK (25.5%) 
and among women attending general practice clinics in 
Australia (22.3%) and the UK (29.9%).[10]
In the current study, we identified two groups of women 
(single infection versus repeat infections) and studied their 
serum antibody response. We aimed to gain insight into why 
some of the individual women get reinfected with Chlamydia 
while some of them only have a single infection. The specific 
aim of the present study was to characterise the systemic 
antibody responses (IgG and IgA) of these two groups of 
individuals against semi-purified elementary bodies (EBs) of 
C. trachomatis serovar D.
MaterIals and Methods
Chlamydia trachomatis cell culture and preparation of 
semi‑purified elementary bodies
C. trachomatis serovar D (ATCC® VR-885™) EBs were prepared 
by infecting HEp-2 cell lines (ATCC® CCL-23) in the presence 
of Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, 
Australia) containing 5% heat-inactivated foetal calf 
serum (FCS) (Life Technologies, Australia), 120 µg/ml 
streptomycin (Sigma-Aldrich, Australia) and 50 µg/ml 
gentamycin (Gibco, Australia), 37°C, 5% CO2.
Once cells reach confluence (>90%), they were infected 
with C. trachomatis serovar D EBs in  sucrose phosphate 
buffer (SPG) by centrifugation at 500 ×g at 28°C for 30 min, 
and afterwards incubated in DMEM containing 2% FCS 
and cycloheximide (1 µg/ml) to inhibit HEp-2 cell protein 
synthesis. 48–50 h postinfection, media was removed from 
the infected flask and replaced with ice-cold SPG. The 
C. trachomatis-infected monolayer was scraped from the 
flask and added to the fresh falcon tube containing glass 
beads (Sigma-Aldrich, Australia) and further vortexed it. 
The suspension was then centrifuged at 500 ×g for 10 min at 
4°C and the supernatant centrifuged at 18,000 ×g for 30 min 
at 4°C. The semi-purified EB was resuspended in SPG and 
stored at −80°C.[11-13]
Serial dilutions of the suspension obtained were used for 
EB quantification. HEp-2 cells were fixed and stained 
with monoclonal antibody-fluorescein isothiocyanate. The 
mean number of inclusion-forming units (IFUs) of the 
single dilutions, counted at the epifluorescence microscope 
(Leica DMLB), was used to calculate the suspension 
titre expressed in IFU/ml.[14-16]
Chlamydia trachomatis serology
Enzyme‑linked immunosorbent assay
Serum IgG and IgA antibody titres for each individual were 
determined, as described by Carey et al., 2010,[17] at two 
different time points (for individual with both single infection, 
as indicated with suffix 3, as well as repeated infection, 
as indicated with suffix 15) as well as at single time point 
(for individuals having single infection only as indicated with 
suffix 3). Two-fold dilutions of serum (50 µl/well) were added 
to the wells of flat-bottom 96-well plates (ThermoLab systems) 
coated with semi-purified EBs of C. trachomatis D (5 × 104 
EBs per well).
Western blot
Western blot assay was used to assess the expression of IgG 
and IgA antibodies of an individual serum sample specific 
to C. trachomatis D semi-purified EBs (1.75 × 105) and 
was performed as described previously.[18] In brief, ~30 µg 
of purified EBs was loaded on 0.75 mm-wide 12% sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis gels 
(110 V for 1 h). Following transfer to a nitrocellulose 
membrane (Pall Corporation, Australia) at 90 V for 1 h, 
membranes were blocked for non-specific binding in blocking 
buffer (5% skimmed milk in 1×  Tris-buffered saline) overnight 
at 4°C or for 2 h at room temperature. For the post-blocking, 
serum samples were added on to the membrane at a dilution 
of 1:1000 in blocking buffer and incubated overnight at 4°C 
or 2 h at room temperature. Membranes were then washed 
4 times with 1 × TBS-T for 5 min each. Secondary antibody 
anti-human IgG and IgA in goat were added at 1:1000 
dilutions in blocking buffer and incubated for 1 h at room 
temperature. Membranes were again washed 4 × with TBS-T 
for 5 min each. Finally, tertiary antibody (Donkey anti-goat 
IgG horseradish peroxidase [HRP] conjugate [for IgG 
detection] and Rabbit anti-goat IgA HRP conjugate [for IgA 
detection] Southern Biotech/Invitro Technologies, Cleveland, 
Australia) was separately added onto the membranes at 1:1000 
in blocking buffer for 1 h at room temperature. Membranes 
were then washed 5 × with TBS-T for 5 min each. Blots were 
visualised for bands by adding enzymatic chemiluminescence 
substrate (Thermo Fisher Scientific, Australia).
In vitro chlamydia neutralisation assay
In vitro neutralisation assay was performed using individual’s 
serum samples collected at two different time points (individual 
with single and repeated infection) as well as single time point, 
according to Kollipara et al.[18] Both cells and inclusions were 
counted under the microscope, and a mean of ten fields of view 
for each well was counted and  the neutralisation percentage 
was determined and compared to media-only controls.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 
version 6 (GraphPad Software, LaJolla, CA, USA). Data 
were presented as mean ± standard deviation from triplicate 
assays. For statistical significance, data were analysed using 
one-way ANOVA and Kruskal–Wallis (nonparametric) tests. 
The P value for significance was set at ≤0.05.
results
In the present study, the serum samples were obtained from 
a cohort (n = 22) of women (enrolled in the Australian 
Chlamydia Treatment Study, ACTS), infected with different 
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Chlamydia serovars. Out of these 22 individuals, five women 
were infected with serovar D, one was infected with serovar 
K, 12 were infected with serovar E and four were infected 
with serovar F. The systemic antibody response (IgG and 
IgA) was measured via enzyme-linked immunosorbent 
assay (further validated through Western blot) among 
the individuals (i.e., homologous vs. homologous and 
homologous vs. heterologous) having single as well as 
those having repeated infections. Further, the neutralising 
ability of different serum samples (infected with different 
Chlamydia serovar) was analysed against semi-purified EBs 
of C. trachomatis serovar D.
Systemic antibody responses of patients infected 
with Chlamydia trachomatis serovar D or K showed 
correlations with reinfection risk
The results showed that some of the individuals (40%) 
infected with serovar D exhibited high IgG and IgA antibody 
titres [1-020-3, 1-186-3, Figure 1a] as well as exhibiting high 
neutralisation level in the in vitro assay [Figure 1c]. Hence, we 
propose that they may have had some level of protection against 
reinfection; patient 1-193-3 was an exception [Figure 1]. 
Some individuals (1-082-3 and 1-233-3) also exhibited a 
high IgG titre but exhibited low neutralisation ability, and 
we propose that they were not protected against subsequent 
C. trachomatis infections. Similarly, in Western blot, there was 
a corresponding increase in IgG response observed among the 
individuals with high IgG titres [Figure 1b]. The individual 
infected with serovar K (only one patient was infected with 
serovar K, 1-049-3) also exhibited a high systemic antibody 
response, as well as high neutralising ability [60%; Figure 2], 
towards infections, and was not reinfected.
Systemic antibody responses of patients infected with 
Chlamydia trachomatis serovar E showed a disconnection 
between immune response and reinfection risk
The level of IgG and IgA antibodies as well as the in vitro 
neutralising ability was also analysed among the individuals 
(n = 12) infected with serovar E (analysed against serovar D). 
The results showed that one of the individuals (infected 
with serovar E, 1-139-3) exhibited a high IgG titre (IgG) 
as well as a high neutralising (60%) ability and was not 
reinfected [Figure 3]. Individuals 1-244-3 and 1-235-3, 
despite exhibiting a high IgG titre and high neutralising levels 
(63-70%), were still reinfected with Chlamydia. Individuals 
1-103-3, 1-052-3, 1-202-3 and 1-010-3, exhibited a very high 
IgG titre but with low neutralising ability (5%–40%) towards 
infection and were found to become reinfected within 6-month 
study period [Figure 3].
Systemic antibody responses of patients infected with 
Chlamydia trachomatis serovar F showed correlations 
with reinfection risk
The level of IgG and IgA antibodies as well as the 
in vitro neutralising ability was also analysed among the 
individuals (n = 4) infected with serovar F (analysed against 
serovar D). The results showed that individuals 1-124-3, 
1-166-3 and 1-156-3 exhibited neither high IgG titre nor high 
neutralising (5%–36%) levels, and therefore, perhaps not 
surprisingly were reinfected, except 2-595-3 [Figure 4].
The systemic antibody response of patients re‑infected 
with Chlamydia trachomatis
Finally, we analysed the systemic antibody response 
among the individuals, who had repeated C. trachomatis 
Figure 1: Systemic antibody response, IgG and IgA, as measured by (a) enzyme‑linked immunosorbent assay, (b) Western blot and (c) in vitro 
neutralisation level of serum sample among individuals after initial Chlamydia trachomatis infections infected with serovar D and tested against 
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infections. A high IgG and IgA response, as well as high 
neutralisation level (75%–90%), was observed among the 
individuals (1-082-15, 1-233-15) infected with serovar D, 
when tested against the same serovar D [Figure 5]. The same 
trend was also observed among the individuals infected 
with different serovars and analysed against serovar D. 
Similarly, high IgG and IgA responses as well as high 
neutralisation levels (52%–97%) were also observed among 
the individuals (1-103-15, 1-244-15, 1-052-15, 1-235-15, 
1-010-15, 1-610-15, 1-212-15, 1-131-15 and 1-586-15) 
infected with serovar E, when tested against the same 
serovar D [Figures 6 and 7] except 1-202-15. Although a high 
Figure 2: Systemic antibody response, IgG and IgA, as measured by (a) enzyme‑linked immunosorbent assay, (b) Western blot and (c) in vitro 
neutralisation level of serum sample among individuals after initial Chlamydia trachomatis infections infected with serovar K and tested against 
semi‑purified elementary bodies of serovar D
b
ca
Figure 3: Systemic antibody response, IgG and IgA, as measured by (a) enzyme‑linked immunosorbent assay, (b) Western blot and (c) in vitro 
neutralisation level of serum sample among individuals after initial Chlamydia trachomatis infections infected with serovar E and tested against 
semi‑purified elementary bodies of serovar D
b
ca
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IgG response was also observed among individuals infected 
with serovar F (1-124-15, 2-595-15) and analysed against 
D, these patients exhibited low neutralisation levels (<40%) 
towards infection [Figure 8].
dIscussIon
C. trachomatis is the aetiological agent for the most prevalent 
bacterial STI in both developed and developing countries. 
The diagnostic rates for C. trachomatis infection have 
increased dramatically over the last decade.[19,20] Repeated 
infections of C. trachomatis are very common and may 
represent reinfection from an untreated partner or treatment 
failure.[21]
The individuals included in this relatively small study 
were studied over a 6-month period and any infection/
reinfection cases were included and recorded. The 
individuals were initially treated with a single oral dose 
of 1 g azithromycin at the time of recruitment into the 
ACTS trial,[17] subsequent to their diagnosis of their initial 
Chlamydia infection (infected with different Chlamydia 
Figure 4: Systemic antibody response, IgG and IgA, as measured by (a) enzyme‑linked immunosorbent assay, (b) Western blot and (c) in vitro 
neutralisation level of serum sample among individuals after initial Chlamydia trachomatis infections infected with serovar F and tested against 
semi‑purified elementary bodies of serovar D
b
ca
Figure 5: Systemic antibody response, IgG and IgA, as measured by (a) enzyme‑linked immunosorbent assay, (b) Western blot and (c) in vitro 
neutralisation level of serum sample among individuals after repeated Chlamydia trachomatis infections infected with serovar D and tested against 
semi‑purified elementary bodies of serovar D
b
ca
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serovars). It has previously been reported that neutralising 
species-specific or serovar-specific antibodies can be 
produced in response to C. trachomatis infection in humans, 
as well as in some animal species.[21] Our results showed 
that a strong humoral immune response, as characterised 
by high serum antibody titres combined with high levels of 
in vitro neutralising antibodies (>60%) in serovars D and 
K, may have been associated with some level of protection 
against reinfections in these individuals. By comparison, 
some other individuals, also infected with serovar D, had 
low neutralisation capacity (<60%), and subsequently these 
individuals were reinfected, indicating no significant level 
of protection. This is in contrast to what was seen in some 
of the patients infected with serovar E, where individuals 
with a high neutralisation (40%–75%) capacity were still 
reinfected. This suggests subtle differences in epitopes 
between serovars D and E and this may relate to their 
in vivo protective ability.
Figure 6: Systemic antibody response, IgG and IgA, as measured by (a) enzyme‑linked immunosorbent assay, (b) Western blot and (c) in vitro 
neutralisation level of serum sample among individuals after repeated Chlamydia trachomatis infections infected with serovar E and tested against 




Figure 7: Systemic antibody response, IgG and IgA, as measured by (a) enzyme‑linked immunosorbent assay, (b) Western blot and (c) in vitro 
neutralisation level of serum sample among individuals after repeated Chlamydia trachomatis infections infected with serovar E and tested against 
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conclusIon
This study shows that individuals infected with serovars D 
or K exhibited a high systemic antibody response (IgG and 
IgA) as well as high neutralisation levels against serovar 
D except those individuals who were infected with serovar 
F. Individuals infected with serovars D and K showed an 
association with humoral immune response and reinfection 
risk (i.e., high immune response = low reinfection risk). 
Similarly, individuals infected with serovar F also showed an 
association with immune response and reinfection risk (i.e. low 
immune response = low reinfection risk). Although some 
of the individuals infected with serovar E exhibited a high 
systemic antibody response as well as high neutralisation level 
against tested serovar D, they showed disconnection between 
associations with humoral immune response and reinfection 
risk (i.e., a high immune response did not always result in 
protection from reinfection).
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